Portal de Periódicos da CAPES

Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study

2024; Elsevier BV; Volume: 24; Issue: 9 Linguagem: Inglês

10.1016/s1473-3099(24)00220-2

1474-4457

Ida Rask Moustsen-Helms, Peter Bager, Tine Graakjær Larsen, Frederik Trier Møller, Lasse S Vestergaard, Morten Rasmussen, Christian Holm Hansen,

vaccines and immunoinformatics approaches

During the 2023 Danish COVID-19 vaccination campaign, an updated monovalent mRNA vaccine targeting the SARS-CoV-2 omicron XBB.1.5 subvariant was administered. However, the rapid spread of a genetically divergent omicron BA.2.86 subvariant, JN.1, since September, 2023, poses potential challenges due to its rapid dominance and possible immune escape. Using national electronic health registry data from all regions of Denmark, we aimed to investigate whether the SARS-CoV-2 subvariant BA.2.86, and its descendant JN.1, differed from other circulating variants in terms of their ability to escape vaccine protection, the risk of infection leading to severe disease, and self-reported symptoms among infected people.